Target adverse event profiles for predictive safety in the post-market setting.

Clicks: 229
ID: 204882
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
We improved a previous pharmacological target adverse-event profile model to predict adverse events on FDA drug labels at the time of approval. The new model uses more drugs and features for learning as well as a new algorithm. Comparator drugs sharing similar target activities to a drug of interest were evaluated by aggregating adverse events from the FDA Adverse Event Reporting System (FAERS), FDA drug labels, and medical literature. An ensemble machine learning model was used to evaluate FAERS case count, disproportionality scores, percent of comparator drug labels with a specific adverse event, and percent of comparator drugs with the reports of the event in the literature. Overall classifier performance was F1 of 0.71, area under the precision-recall curve of 0.78, and area under the receiver operating characteristic curve of 0.87. Target adverse-event analysis continues to show promise as a method to predict adverse events at the time of approval.
Reference Key
schotland2020targetclinical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Schotland, Peter;Racz, Rebecca;Jackson, David B;Soldatos, Theodoros G;Levin, Robert;Strauss, David;Burkhart, Keith;
Journal clinical pharmacology and therapeutics
Year 2020
DOI
10.1002/cpt.2074
URL
Keywords
Machine learning Atrial fibrillation neural networks atrial fibrillation screening stroke prevention targeted screening

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.